LAVA Therapeutics N.V. announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for LAVA-051, the Company's lead product candidate for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML). The Phase 1/2a clinical trial currently includes patients with relapsed or refractory CLL and MM. AML patients will be included later in the study.

In October 2021, the FDA granted Orphan Drug Designation for LAVA-051 for the treatment of CLL.